Prepandemic levels of cytokines and immunoglobulins and risk of SARS-CoV-2 infection and COVID-19 in the general population of Barcelona.

Background: From a public health perspective it is remarkable that there are yet no longitudinal studies in the general population investigating the influence of the basal immune state, measured before the pandemic, on the risk of SARS-CoV-2 infection and COVID-19.

Objective: To investigate the specific and combined effects of personal levels of cytokines and immunoglobulins-measured in individuals' blood 4 years before the pandemic-on the risk of SARS-CoV-2 infection and COVID-19 in a general population.

Methods: We conducted a prospective cohort study in 240 individuals from the general population of Barcelona.

Risk factors associated with the development of complications after a hip fracture.

Aims: Mortality after a hip fracture has declined in recent years, but the risk of complications remains high. The aim of this study was to identify non-modifiable and, specifically, modifiable factors associated with the development of complications after hip fracture.

Methods: This was a multicentre, prospective cohort study of adults aged ≥ 60 years with a hip fracture who were treated in 77 hospitals in England, Wales, and Northern Ireland between July 2014 and November 2021.

Pioneering microbial synthesis of gangliosides in the filamentous fungus Ashbya gossypii.

Gangliosides are essential glycosphingolipids critical in neurodevelopment and cell signaling. Traditionally sourced from animal tissues, their production raises ethical concerns and faces challenges in scalability and cost. Chemoenzymatic methods have emerged as alternatives but lack flexibility and broad industrial applicability of microbial systems.

Antibody and B-Cell Responses to PHH-1V81 XBB.1.16-Adapted SARS-CoV-2 Booster Vaccination Are Associated With Variant Neutralization.

Immune escape by SARS-CoV-2 emerging variants jeopardizes vaccine effectiveness, necessitating new immunization strategies. Here, we assessed the antibody B-cell response in 40 individuals receiving either the PHH-1V81 XBB.1.

Treatment of obesity with GLP-1 receptor agonist after bariatric surgery: Real-world evidence.

Introduction: Approximately 25-30% of patients undergoing bariatric surgery (BS) experience weight regain or suboptimal weight loss. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as a therapeutic option in these cases.

Aim: To evaluate the effectiveness of GLP-1 RAs in managing weight regain and suboptimal weight response after BS in a real-world setting.